Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice

Gene Therapy

Volumn 7, Issue 17, 2000, Pages 1447-1457

  Braun, S ^a   Thioudellet, C ^a   Rodriguez, P ^a   Ali Hadji, D ^a   Perraud, F ^a   Accart, N ^a   Balloul, J M ^a   Halluard, C ^a   Acres, B ^a   Cavallini, B ^a   Pavirani, A ^a  

^a TRANSGENE S A   (France)

Author keywords

Duchenne; Dystrophin; Gene therapy; Immunology; Mdx; Plasmid

Indexed keywords

DNA ANTIBODY; DYSTROPHIN; EDETIC ACID; MONOCLONAL ANTIBODY; PLASMID DNA; PROTEIN ANTIBODY; SODIUM CHLORIDE; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; GENE THERAPY; HUMORAL IMMUNITY; IMMUNE RESPONSE; MALE; MOUSE; MOUSE STRAIN; MUSCLE TISSUE; MYOSITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SPECIES DIFFERENCE; T LYMPHOCYTE;

ANIMALIA;

EID: 0033795497     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301261     Document Type: Article

References (69)

1. Dystrophin: The protein product of the Duchenne muscular dystrophy locus
2. Gene therapy in Duchenne muscular dystrophy
3. Gene therapy of Duchenne muscular dystrophy
4. X chromosome-linked muscular dystrophy (mdx) in the mouse
5. The molecular basis of muscular dystrophy in the mdx mouse: A point mutation
6. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin
7. Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice
8. Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs
9. High-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: Prolongation of expression with immunosuppression
10. Dystrophin acts as a transplantation rejection antigen in dystrophin-deficient mice: Implication for gene therapy
11. Myoblast transfer in the treatment of Duchenne's muscular dystrophy
12. Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy
13. The fate of individual myoblasts after transplantation into muscles of DMD patients
14. Human myoblast transplantation between immunohistocompatible donors and recipients produces immune reactions
15. Myoblast implantation in Duchenne muscular dystrophy: The San Francisco study
16. Antibody formation after myoblast transplantation in Duchenne-dystrophic patients, donor HLA compatible
17. Myoblast transfer in Duchenne muscular dystrophy
18. Human myoblast transplantation: Preliminary results of 4 cases
19. Myoblast transplantation between monozygotic twin girl carriers of Duchenne muscular dystrophy
20. First human myoblast transfer therapy continues to show dystrophin after 6 years
21. Meeting of the cell transplantation society in Miami
22. Lymphocyte infiltration following allo- and xenomyoblast transplantation in mdx mice
23. Immune reactions after myoblast transplantation in mouse muscles
24. Adenovirus-mediated dystrophin minigene transfer improves muscle strength in adult dystrophic (mdx) mice
25. Myoblast transfer and gene therapy in muscular dystrophies
26. Direct gene transfer into mouse muscle in vivo
27. Dystrophin expression improves myofiber survival in mdx muscle following intramuscular plasmid DNA injection
28. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle
29. Immune-mediated destruction of transfected muscle fibers after direct gene transfer with antigen-expressing plasmid DNA
30. Coisogenic all-plus-one immunization: A model for identifying missing proteins in null-mutant conditions. Antibodies to dystrophin in mdx mouse after transplantation of muscle from normal coisogenic donor
31. Successful histocompatible myoblast transplantation in dystrophin-deficient mdx mouse despite the production of antibodies against dystrophin
32. ELISA quantitation of dystrophin for the diagnosis of Duchenne and Becker muscular dystrophies
33. A quantitative ELISA for dystrophin
34. Quantitative estimation of dystrophin protein: A sensitive and convenient two-antibody sandwich ELISA
35. Gene transfer into canine myoblasts
36. Pathological responses of rat skeletal muscle to a single subcutaneous injection of a toxin from the venom of the Australian tiger snake, Notechis scutatus scutatus
37. Utilization of an antibody specific for human dystrophin to follow myoblast transplantation in nude mice
38. Somatic reversion/suppression of the mdx phenotype in vivo
39. Expression of factor VII by muscle cells in vitro and in vivo following direct gene transfer: Modelling gene therapy for haemophilia
40. Do DNA vaccines induce autoimmune disease?
41. Antibodies to DNA
42. Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer
43. Adenovirus-mediated gene transfer: Influence of transgene, mouse strain and type of immune response on persistence of transgene expression
44. Immune responses, not promoter inactivation, are responsible for decreased long-term expression following plasmid gene transfer into skeletal muscle
45. Characterization of plasmid DNA transfer into mouse skeletal muscle: Evaluation of uptake mechanism, expression and secretion of gene products into blood
46. Dystrophin-positive fibers in Duchenne dystrophy: Origin and correlation to clinical course
47. The frequency of revertants in mdx mouse genetic models for Duchenne muscular dystrophy
48. Serum antibodies to the delivered dystrophin sequence after cardiac transplantation in a patient with Becker's muscular dystrophy
49. Structure and mutation of the dystrophin gene
50. DNA vaccines
51. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response
52. Induction of antigen-specific cytotoxic T lymphocytes in human by a malaria DNA vaccine
53. Gene vaccination with naked plasmid DNA: Mechanism of CTL priming
54. Heterogeneity of dystrophin expression in patients with Duchenne and Becker muscular dystrophy
55. Expression of full-length utrophin prevents muscular dystrophy in mdx mice
56. The efficient expression of intravascularly delivered DNA in rat muscle
57. A ubiquitous mammalian expression vector, pHMG, based on a housekeeping gene promoter
58. Phase separation of integral membrane proteins in Triton X-114 solution
59. Gene therapy by intramuscular injection of plasmid DNA: Studies on firefly luciferase gene expression in mice
60. Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice
61. Cultured normal and genetically abnormal human muscle
62. A new technique for the assay of infection of human adenovirus 5 DNA
63. A modified micro-Bradford procedure for elimination of interference from sodium dodecyl sulfate, other detergents, and lipids
64. Der Pockenimpfstamm MVA: Larker, genetische Struktur, erfahrungen mit der parenteralen Schutzimpfung und Verhalten im abswehrgeschwachten Organismus
65. Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA
66. Inhibition of SV40 replication in simian cells by specific pBR322 DNA sequences
67. Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors
68. Human dystrophin gene transfer: Production and expression of a recombinant cDNA-based gene